Hemostemix, with its groundbreaking therapy at the Wound Care Conference in Florida

Announcement

Hemostemix Inc., a known champion in regenerative medicine, will be at the Innovations in Wound Care Conference in Key West, Florida, scheduled from December 11-14, 2025. The company will flaunt its world-class angiogenic cell therapy, ACP-01. The therapy, which heals ulcers, reduces pain, improves quality of life and regenerates circulation for patients seeking advanced wound care needs involving Critical Limb-T6hraetning Ischemia (CLTI) and Peripheral Arterial Diseases.

Last week, the company completed a Grand Rounds presentation held at the University of Florida Department of Vascular Surgery, presenting Dr Fraser Henderson, a Neurosurgeon. The sessions in the rounds examined clinical insights from the 498 subjects' treatments throughout the five Phase 1 trials, one retrospective study and one Phase 2 double-blind randomised controlled trial. The four Hemostemix studies precisely wound healing that protected limbs from amputation, consisting of the double blind randomised phase 2 trial, discarding the option of CLTI subjects.

Need for Wound Healing Therapy and investments

The ACP-01 has been available under Florida SB-1768, serving, curing and healing around 500,000 Floridians who live with pain connected to the non-healing wounds. Wound healing is a crucial and most neglected topic among many individuals, but the therapy is the awareness that reminds one of a fit and healthy lifestyle. The wound care market is expected to grow at a CAGR of 5-6% reaching $700-$800 million in the next five years.

The Hemostemix are transforming the business and development game in the global wound care market as it operates vastly with the confidence and expectation to expand $20 billion by 2030 with its characterisation by vascular disease, chronic wounds and increased rates of diabetes. With the existing excellence of the ACP-01 already on the market ground under Florida SB-1768 and backed by the comprehensive clinical evidence. Following this excellence, the company has been ranked as the first transformer in regenerative medicine for limb salvage.

The company, through its trading pattern, provides key insights to their investors about the elevated sector with prominent unmet medical needs. The President and CEO of Hemostemix, Thomas Smeenk, proudly said, “Our mission is very simplified yet profound, which involves healing wounds, treating pain that might not have bothered to be healed, further improving patients’ quality of life and protecting limbs. The ACP-01 is the popular known therapy for healing wounds and regenerating circulation more effectively, healing the area where traditional options failed to reach.”